UCB - Selling And Administration Expenses


UCB reported EUR1.47B in Selling and Administration Expenses for its fiscal semester ending in December of 2025.





Selling And Administration Expenses Change Date
Alcon AG USD 901M 36M Dec/2025
Amarin USD 18.97M 1.03M Dec/2025
argenx SE USD 429.62M 93.32M Dec/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
Bayer EUR 4.05B 647M Dec/2025
Galapagos EUR 44.42M 9.87M Dec/2025
Genmab DKK 208M 60M Dec/2025
GlaxoSmithKline GBP 2.68B 518M Dec/2025
GRIFOLS EUR 275.3M 9.7M Dec/2025
Hikma Pharmaceutical USD 288M 149M Dec/2025
Merck EUR 1.6B 136M Dec/2025
Novartis USD 3.44B 128M Dec/2025
Orion EUR 110.7M 26.1M Dec/2025
Recordati EUR 171.38M 15.6M Sep/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sanofi EUR 2.75B 455M Dec/2025
UCB EUR 1.47B 193M Dec/2025
Unibail Rodamco EUR 94.8M 4.8M Dec/2025